Coeptis Therapeutics Inc. (OTCPK:COEP) agreed to acquire TLR5 Immunity Receptor Agnonist Platform from Statera Biopharma, Inc. (NasdaqCM:STAB) for $6 million on April 6, 2022. The consummation of the transaction is contingent upon negotiation of a definitive agreement and satisfaction of a number of closing conditions, including a financing contingency.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2704 USD | -0.33% | -6.01% | -65.51% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
0.2704 USD | -0.33% | -6.01% | 97.91L | ||
0.0006 USD | -.--% | -14.29% | 43.55T | ||
1st Jan change | Capi. | |
---|---|---|
-65.51% | 97.91L | |
+40.73% | 73TCr | |
+32.83% | 59TCr | |
-6.30% | 35TCr | |
+15.15% | 32TCr | |
+4.05% | 28TCr | |
+15.00% | 24TCr | |
+9.78% | 21TCr | |
-5.52% | 20TCr | |
+6.17% | 16TCr |
- Stock Market
- Equities
- COEP Stock
- News Coeptis Therapeutics Holdings, Inc.
- Coeptis Therapeutics Inc. agreed to acquire TLR5 Immunity Receptor Agnonist Platform from Statera Biopharma, Inc. for $6 million.